ClinicalTrials.gg
CompletedNCT04589403Updated Sep 15, 2025

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

A Phase 1 interventional study of OPT101 in Healthy, sponsored by Op-T LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Op-T LLC · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.

Read the detailed description

2 part study description:

  • an initial Phase 1a single ascending dose (SAD) phase to identify a safe dose of OPT101.

Dose escalation will be by a factor of 2.6: 0.16, 0.42, 1.1, 2.8 and 7.3mg/kg.

  • a Phase 1b multiple ascending dose (MAD) phase to measure safety and clinical effects of the highest and next to highest dose of OPT101 that are found to be safe in Phase 1a.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Op-T LLC is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion :

  • Able and willing to give for the trial
  • Male or female aged ≥18 years on the day of signing informed consent
  • Is medically stable based on physical examination, medical history, laboratory results, and vital signs performed at screening
  • Women of must have a negative highly sensitive serum test (beta-human chorionic gonadotropin) at screening and a negative urine pregnancy test at the Visit 1 Day 1 prior to receiving the product.
  • Women must agree to use one of the following methods of for the duration of the clinical trial: systemic hormonal contraceptive (oral, injected, transdermal), intrauterine device, double barrier (e.g., cervical cap or diaphragm with condom or spermicide). Men with female partners must agree to use double barrier contraception, unless their partner is using systemic hormonal contraceptives or has an intrauterine device.

Exclusion:

  • Is over the age of 55 years old
  • Positive COVID test at screening/baseline
  • Has an active fever or has recently been exposed to a COVID-19 patient.
  • Currently has or had a history of
  • Has an immune deficiency syndrome (for example, severe combined immunodeficiency syndrome, T-cell deficiency syndromes, B-cell deficiency syndromes, or chronic granulomatous disease), or bone marrow or organ transplantation, or a disease associated with lymphopenia
  • Is currently being treated for an disease/s
  • Subjects with a history of venous and arterial thromboembolic events including, but not limited to, the following: deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, , or arterial insufficiency causing digital gangrene should be excluded. In addition, subjects with recent immobilization or recent surgery, should be excluded. Subjects with a history of abnormal prothrombotic laboratories such as congenital or inherited deficiency of antithrombin III, protein C, protein S, or confirmed diagnosis of antiphospholipid syndrome should also be excluded.
  • Has active infections, is prone to infections or has chronic, recurrent or opportunistic infectious disease, including but not limited to, Epstein-Barr virus (EBV), cytomegalovirus (CMV) chronic renal infection, chronic chest infection, sinusitis, recurrent urinary tract infection, Pneumocystis carinii, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis or an open, draining, or infected non-healing skin wound or ulcer
  • Has recent or active hepatitis A infection, current/chronic and infection, or infection. Participants with immunity to hepatitis B from previous infection (defined as negative HBsAg, positive anti-HBc, and positive hepatitis B surface antibody [anti-HBs]) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) may be eligible to participate.
  • Has history of immune suppression disorders
  • Has received a live (attenuated) vaccine within the last 60 days, including subjects who plan to receive live (attenuated) vaccines during the study or within 60 days after the final dose of study treatment.
  • Has received influenza vaccine within 14 days of screening.
  • Has received a biologic or immunotherapy in the last 6 months (If receiving allergy shots with stable dosing, is acceptable)
  • Has received prescription or non-prescription medication and in the opinion of the Investigator, the product will interfere with the study procedures or data integrity or compromise the safety of the subject.
  • Subjects with abnormal laboratory test values in screening blood samples. In particular subjects with the following should be excluded:

Subjects with abnormal coagulation panel at screening such as abnormal PT or or fibrinogen

Abnormal liver function tests:

Liver enzyme abnormalities (except in the case of known Gilbert's syndrome) or ALT ≥3x and total ≥2x ULN AST or ALT ≥5x ULN AST or ALT ≥3x ULN if associated with appearance or worsening of rash or hepatitis symptoms Abnormal counts (\<150,000/mcL or > 450,000/mcL) Abnormal white blood cell counts (\<3E3/uL or > 11E3/uL ) Abnormal (\<60 mL/min/1.73m2) Elevated IgE level above 50 IU/mL

  • Subjects planning to undergo Elective procedures or surgeries at any time after signing the ICF through the follow-up visit.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting withInclusion :
  • Able and willing to give informed consent for the trial
  • Male or female aged ≥18 years on the day of signing informed consent
  • Is medically stable based on physical examination, medical history, laboratory results, and vital signs performed at screening
  • Women of childbearing potential must have a negative highly sensitive serum test (beta-human chorionic gonadotropin) at screening and a negative urine pregnancy test at the Visit 1 Day 1 prior to receiving the investigational product.
  • Women must agree to use one of the following methods of birth control for the duration of the clinical trial: systemic hormonal contraceptive (oral, injected, transdermal), intrauterine device, double barrier (e.g., cervical cap or diaphragm with condom or spermicide). Men with female partners must agree to use double barrier contraception, unless their partner is using systemic hormonal contraceptives or has an intrauterine device.

Exclusion:

  • Is over the age of 55 years old
  • Positive COVID test at screening/baseline
  • Has an active fever or has recently been exposed to a COVID-19 patient.
  • Currently has or had a history of malignancy
  • Has an immune deficiency syndrome (for example, severe combined immunodeficiency syndrome, T-cell deficiency syndromes, B-cell deficiency syndromes, or chronic granulomatous disease), or bone marrow or organ transplantation, or a disease associated with lymphopenia
  • Is currently being treated for an autoimmune disease/s
  • Subjects with a history of venous and arterial thromboembolic events including, but not limited to, the following: deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, or arterial insufficiency causing digital gangrene should be excluded. In addition, subjects with recent immobilization or recent surgery, should be excluded. Subjects with a history of abnormal prothrombotic laboratories such as congenital or inherited deficiency of antithrombin III, protein C, protein S, or confirmed diagnosis of antiphospholipid syndrome should also be excluded.
  • Has active infections, is prone to infections or has chronic, recurrent or opportunistic infectious disease, including but not limited to, Epstein-Barr virus (EBV), cytomegalovirus (CMV) chronic renal infection, chronic chest infection, sinusitis, recurrent urinary tract infection, Pneumocystis carinii, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis or an open, draining, or infected non-healing skin wound or ulcer
  • Has recent or active hepatitis A infection, current/chronic hepatitis B and hepatitis C infection, or HIV infection. Participants with immunity to hepatitis B from previous infection (defined as negative HBsAg, positive anti-HBc, and positive hepatitis B surface antibody [anti-HBs]) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) may be eligible to participate.
  • Has history of immune suppression disorders
  • Has received a live (attenuated) vaccine within the last 60 days, including subjects who plan to receive live (attenuated) vaccines during the study or within 60 days after the final dose of study treatment.
  • Has received influenza vaccine within 14 days of screening.
  • Has received a biologic or immunotherapy in the last 6 months (If receiving allergy shots with stable dosing, is acceptable)
  • Has received prescription or non-prescription medication and in the opinion of the Investigator, the product will interfere with the study procedures or data integrity or compromise the safety of the subject.
  • Subjects with clinically significant abnormal laboratory test values in screening blood samples. In particular subjects with the following should be excluded:

Subjects with abnormal coagulation panel at screening such as abnormal PT or aPTT or fibrinogen

Abnormal liver function tests:

Liver enzyme abnormalities (except in the case of known Gilbert's syndrome)

AST or ALT ≥3x ULN and total bilirubin ≥2x ULN AST or ALT ≥5x ULN AST or ALT ≥3x ULN if associated with appearance or worsening of rash or hepatitis symptoms Abnormal platelet counts (\<150,000/mcL or > 450,000/mcL) Abnormal white blood cell counts (\<3E3/uL or > 11E3/uL ) Abnormal eGFR (\<60 mL/min/1.73m2) Elevated IgE level above 50 IU/mL

  • Subjects planning to undergo Elective procedures or surgeries at any time after signing the ICF through the follow-up visit.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
  • Recent history of bleeding or bleeding disorders or any condition whereby in the opinion of the treating investigator giving anti-coagulation during treatment would be .
  • History of to antihistamines.
  • Weight is over 350lbs.
  • Subjects with active drug or alcohol abuse within 1 year prior to screening
  • Subject is participating in a clinical trial of another investigational drug or device, including subjects who have participated in another study for a duration of 5 half-lives of the investigational agent.
  • Investigators could exclude subjects with any medical condition, including, but not limited to, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or a psychiatric condition that, in the opinion of the Investigator, could compromise the participant's ability to participate in this study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
14 participants (actual)

Study arms

  • Placebo comparator
    0.9% Sodium Chloride Injection USP

    Placebo will be 50 mL normal saline (Sodium Chloride), USP sterile solution administered by IV infusion over 30 minutes.

    Drug: OPT101

  • Experimental
    OPT101

    The starting dose for the Phase 1a study is 0.16 mg/kg, which is 35-fold lower than the dog NOAEL (10mg/kg), on a mg/m2 basis. The dosing frequency for the MAD study was selected based on dosing performed in the supporting animal model studies. For an additional safety factor, the dose and volume infusion rates for the 0.16 mg/kg dose in humans will be 67-fold and 14-fold lower than the dogs dosed at 10mg/kg/min and mL/kg/min basis, respectively. For both Phase 1a and 1b, OPT101 will be administered by a slow IV infusion over 30 minutes.

    Drug: OPT101

Interventions

  • DrugOPT101

    15-mer peptide with sequence based on the mouse CD154 domain interacting with CD40

    Also known as: 15-mer peptide

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Incidence of abnormal vital signs and abnormal laboratory values

    Time frame: 21 days

  2. Rate and type of adverse events during and after infusion of OPT101 or placebo

    Collection of all adverse events

    Time frame: 48 hours

  3. Incidence of vital signs

    Continuous telemetry monitoring

    Time frame: 48 hours

  4. Incidence of abnormal laboratory values

    Blood laboratory results and iStat results onsite

    Time frame: 21 days

  5. Definition of maximum tolerated (MTD) single and repeated doses of OPT101

    DMC and Safety and Tolerability

    Time frame: 48 hours

Secondary outcomes

  1. Determine pharmacokinetic (PK) Parameters (AUC0-t, Cmax, CL/F, t1/2)

    PK samples will be taken at 8 time points during the infusion

    Time frame: 8 hours

  2. Development of anti-drug antibodies after 1 or more infusions

    Anti-drug antibodies will be collected 2 times during study

    Time frame: 2 weeks- 1 prior to infusion and day 15

07

Study locations

1 site
  • IMMUNOe Research
    Centennial, Colorado 80112, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Sep 2021, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2020
First posted
Oct 19, 2020
StartActual
Feb 18, 2021
Primary completionActual
Sep 27, 2021
CompletionActual
Sep 27, 2021
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04589403
Lead sponsor
Op-T LLC
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Feb 18, 2021
Primary completion
Sep 27, 2021
Completion
Sep 27, 2021
Last update
Sep 15, 2025

Study contacts

Isaac Melamed, MD
principal investigator · IMMUNOe Health Centers

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: OPT101

Start the discussion